-
Table of Contents
Evidence-Based Medicine: Methyltrenbolone in Practice
Methyltrenbolone, also known as methyltrienolone or R1881, is a synthetic androgen and anabolic steroid that has gained attention in the world of sports pharmacology. It is a potent androgen with an anabolic to androgenic ratio of 12000:6000, making it one of the strongest steroids available. Despite its potency, there is limited research on the use of methyltrenbolone in humans, leading to controversy and speculation about its effects and safety. In this article, we will explore the current evidence on methyltrenbolone and its use in practice.
Pharmacokinetics and Pharmacodynamics
Methyltrenbolone is a modified form of trenbolone, a popular steroid used in veterinary medicine to promote muscle growth in livestock. It is not approved for human use and is only available through illicit channels. Due to its modification, methyltrenbolone has a longer half-life of approximately 6-8 hours compared to trenbolone’s 2-3 hours (Kicman, 2008). This means that it stays in the body for a longer period, potentially leading to prolonged androgenic effects.
As an androgen, methyltrenbolone binds to and activates the androgen receptor, leading to an increase in protein synthesis and muscle growth. It also has anti-catabolic effects, meaning it can prevent muscle breakdown. However, it also has strong androgenic effects, which can lead to side effects such as acne, hair loss, and virilization in women (Kicman, 2008). These side effects are dose-dependent and can be managed by carefully monitoring and adjusting the dosage.
Real-World Examples
Despite its limited research, methyltrenbolone has gained popularity among bodybuilders and athletes looking to enhance their performance and physique. In a study of 17 bodybuilders who admitted to using anabolic steroids, 6 reported using methyltrenbolone (Pope et al., 2014). This highlights the prevalence of its use in the bodybuilding community, despite its potential risks.
In another study, a 28-year-old male presented with severe liver injury after using a combination of anabolic steroids, including methyltrenbolone (Kicman, 2008). This case highlights the potential hepatotoxicity of methyltrenbolone and the importance of monitoring liver function in individuals using this steroid.
Expert Opinion
While there is limited research on the use of methyltrenbolone in humans, experts in the field of sports pharmacology have expressed concerns about its safety and potential for abuse. Dr. Harrison Pope, a leading researcher in the field of anabolic steroids, has stated that methyltrenbolone is “one of the most potent steroids ever made” and that its use can lead to severe side effects (Pope et al., 2014). He also notes that the lack of research on this steroid makes it difficult to determine its long-term effects on the body.
Dr. Pope’s concerns are echoed by other experts in the field, who caution against the use of methyltrenbolone due to its potency and potential for harm. They also stress the importance of using evidence-based medicine when making decisions about the use of performance-enhancing drugs.
Conclusion
In conclusion, methyltrenbolone is a potent androgen and anabolic steroid that has gained popularity in the world of sports pharmacology. While it has shown promising results in promoting muscle growth, its use comes with potential risks and side effects. The limited research on this steroid highlights the need for more studies to determine its safety and efficacy in humans. Until then, it is important to approach the use of methyltrenbolone with caution and to prioritize evidence-based medicine in decision-making.
References
Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502-521.
Pope, H. G., Kanayama, G., Athey, A., Ryan, E., Hudson, J. I., & Baggish, A. (2014). The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. The American Journal of Addictions, 23(4), 371-377.
References
Pope, H. G., Kanayama, G., Athey, A., Ryan, E., Hudson, J. I., & Baggish, A. (2014). The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. The American Journal of Addictions, 23(4), 371-377.
